T Cell Lymphomas
Conference Coverage
Why a mycosis fungoides diagnosis takes so long
“Judicious use of molecular studies may help in establishing the diagnosis, but I don’t think any one molecular study is ever going to be our home...
Conference Coverage
Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL
Conference Coverage
Duvelisib response rate encouraging in phase 2 PRIMO trial of patients with r/r PTCL
Conference Coverage
Allogeneic transplant leads to durable remissions in T-cell lymphomas
Retrospective study demonstrates overall survival over 50% at 5 years, though transplant-related mortality and graft-versus-host disease need to...
From the Journals
Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia
The presence of “many or very many nevi [moles]” was particularly associated with the risk of CLL.
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
American Cancer Society update: ‘It is best not to drink alcohol’
Feature
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
From the Journals
Lymphocyte, monocyte data can predict treatment response in follicular lymphoma
Blood cell count values at diagnosis can predict the clinical outcomes in follicular lymphoma.
Conference Coverage
Stage I mycosis fungoides is the general dermatologist’s bailiwick
LAHAINA, HAWAII – “Mycosis fungoides is a great masquerader.”
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...